Anthony R. ProsserAnthony R. Prosser, Ph. D.

Anthony R. Prosser, Ph. D., is a Patent Agent with Knowles Intellectual Property Strategies, LLC.  Dr. Prosser focuses on complex organic chemistry matters including new chemical compounds, synthetic methodology, due diligence, freedom to operate and patentability investigations.

In 2015, Dr. Prosser received his Ph. D. in Organic Chemistry from Emory University under Dr. Dennis S. Liotta, the Samuel Candler Dobbs Professor of Chemistry and an internationally acknowledged leader in academic drug discovery.  At Emory, Dr. Prosser was awarded a Woodruff Fellowship as well as an NSF Graduate Fellowship. Dr. Prosser’s graduate work focused on the development of a direct transformation of esters to ketones with no required purification step. This reaction allowed for the development of a series of molecules that inhibit CXCR4, CCR5, and HIV Reverse Transcriptase simultaneously, each of which is currently being pursued as a single agent treatment of HIV.

Dr. Prosser’s doctoral research was featured in Chemical and Engineering News, Science Daily (, A&U (, and was awarded first place in the Emory University 3 Minute Thesis Competition (

Anthony R. Prosser lab

Dr. Prosser received his B. S. in Chemistry in 2011 from the University of Kansas, where he received the University’s Goldwater Nomination, the Darlington Research Award, and the American Institute of Chemists Fellow Award for Excellence in Chemistry. At the University of Kansas Dr. Prosser researched synthetic methodology for the production of new donor acceptor cyclopropanes for use as synthetic tools in the production of more complex natural or medicinal products.

Dr. Prosser has authored or co-authored ten publications in peer-reviewed journals, and given presentations at over a dozen conferences.  Emory University filed a patent application on his graduate work to cover the synthesis and use of his new HIV agents.  His publications include:

One-Pot Transformation of Esters to Analytically Pure Ketones: Methodology and Application in Process Development
Anthony R. Prosser, and Dennis C. Liotta
56, 3005-3007 Tetrahedron Letters 2015


Discovery of Novel N-Aryl Piperazine Cxcr4 Antagonists.
Zhao, H.; Prosser, A. R.; Liotta, D. C.; Wilson, L. J.
25, 4950-4955 Bioorg. Med. Chem. Lett. 2015


Pyrazolo-Piperidines Exhibit Dual Inhibition of Ccr5/Cxcr4 Hiv Entry and Reverse Transcriptase.
Cox, B. D.; Prosser, A. R.; Sun, Y.; Li, Z.; Lee, S.; Huang, M. B.; et al.
6, 753-757 ACS Medicinal Chemistry Letters 2015


NMDA Receptor Modulators: an Updated Patent Review (2013-2014)
Katie L. Strong, Yao Jing, Anthony R Prosser, Stephen F. Traynelis, and Dennis C. Liotta
24, 1349-1366 Expert opinion on therapeutic patents 2014


Anti-HIV Small Molecule Binding in the Peptide Sub-Pocket of the CXCR4:CVX15 Crystal Structure
Bryan D. Cox, Anthony R. Prosser, Brooke M. Katzman, Ana A. Alcaraz, et al.
15(11) 1614-1620 Chem. BioChem. 2014


Formal Substitution of Bromocyclopropanes with Nitrogen Nucleophiles
Joeseph E. Banning, Jacob Getillon, Pavel G.. Ryabchuk, Anthony R. Prosser, et al.
78(15) 7601-7616 J. Org. Chem. 2013


Discovery of Tetrahydroisoquinoline-Based CXCR4 Antagonist
Valarie M. Trauax, Huanyu Zhao, Brooke M. Katzman, Anthony R. Prosser, et al.
4(11) 1025-1030 ACS Med. Chem. Lett. 2013


Diastereoselective Control in Formal Nucleophilic Substitution of Bromocyclopropanes with Oxygen and Sulfur-Based Nucleophiles
Joseph E. Banning, Anthony R. Prosser, Bassam K. Alnasleh, et al.
76(10), 3968-3986, J. Org. Chem. 2011


Formal Nucleophilic Substitution of Bromocyclopropanes with Amides en route to Conformationally Constrained -Amino Acid Derivatives
Anthony R. Prosser, Joseph E. Banning, Marina Rubina, Michael Rubin
12(18), 3968-3971, Org. Lett. 2010


Thermodynamic Control of Diastereoselectivity in the Formal Nucleophilic Substitution of Bromocyclopropanes.
Joseph E. Banning, Anthony R. Prosser, Michael Rubin
12(7), 1488-1491, Org. Lett. 2010